Mulberry Medical Associates, False Claims Act, Alabama 2020
A Montgomery, AL medical practice has agreed to pay $425,000 in a civil settlement to resolve allegations that it violated the False Claims Act. The allegations involved the importation and distribution of foreign, non-Food and Drug Administration (FDA) approved pharmaceutical products prohibited under the Food, Drug, and Cosmetic Act.
Mulberry Medical Associates, a group medical practice in Montgomery, Alabama, specializes in internal medicine. The government’s investigation revealed that the practice purchased and administered certain unlicensed and foreign-made pharmaceutical products, or “subject products,” that were meant to be distributed only in foreign markets. These subject products were less expensive than their FDA counterparts marketed in the United States and included versions of Orthovisc, Supartz, Prolia, and Aclasta, which are used to treat patients with osteoarthritis and osteoporosis.
The settlement addresses allegations that, from September 2011 through March 2017, Mulberry Medical Associates knowingly submitted false claims for and related to the use of the subject products to Medicare, Medicaid and the Federal Employees Health Benefits Program (FEHBP). Federal health care programs reimburse for prescription drugs at a set rate based on the average sales price of the respective FDA approved, physician-administered drug in the United States. Therefore, Mulberry Medical Associates was able to profit from the margin between the reimbursement rates received based on FDA approved drugs, and the lower amounts paid for the unauthorized subject products. The United States contends that the subject products were not eligible for reimbursement by the federal health care programs because they had not received final marketing approval from the FDA.
“This settlement shows that the United States government is working to identify companies that place profit ahead of patient safety, and hold them accountable,” stated Acting U.S. Attorney Sandra J. Stewart. “Maximizing revenues by skirting regulations that are designed to protect patients has no place in our healthcare system. Companies should never allow financial considerations to influence their decision-making process when the health and welfare of the American citizen is at stake.”
“Doctors are entrusted with caring for their patients and obtaining and using safe, U.S. approved drugs on their patients,” said Derrick L. Jackson, Special Agent in Charge at the U.S. Department of Health and Human Services, Office of Inspector General in Atlanta. “Mulberry Medical Associates put their financial gain above the health and safety of local residents. HHS-OIG continues to focus resources on those who obtain and use unapproved drugs on patients. Patient safety is a top priority.”
The investigation into Mulberry Medical Associates was conducted by the U.S. Department of Health and Human Services-Office of Inspector General, the U.S. Office of Personnel Management-Office of Inspector General, the U.S. Food and Drug Administration-Office of Criminal Investigations, and the Health Care Fraud Investigator of the U.S. Attorney’s Office. The United States was represented by Assistant United States Attorney Stephen D. Wadsworth of the Office’s Civil Division.
The claims resolved by the settlement are allegations only, and there has been no determination of liability.”
Related Federal Cases
- Bodega Importadora de Pallets, False Deposit Insurance Claims, Wash… · Alabama
- Rite Aid Corporation, Controlled Substances Act Violations, USA, 2023 · Alabama
- SouthernCare Inc, Hospice Fraudulent Claims, Birmingham AL, 2023 · Alabama
- Utoppia Inc. and Officers Ordered to Cease False Deposit Insurance … · Alabama
- Federal Deposit Insurance Corporation, Community Reinvestment Act C… · Alabama
Key Facts
- State: Alabama
- Category: Fraud & Financial Crimes
- Source: DOJ Press Release â†â€â€
ðŸâ€Â’ Get the grimiest stories delivered weekly. Subscribe free →
MORE FEDERAL CRIME NEWS
US NewsUS NewsUS NewsUS News